EQS-PVR: BB BIOTECH AG: Disclosure of Shareholdings

EQS Voting Rights Announcement: BB BIOTECH AG BB BIOTECH AG: Disclosure of Shareholdings 10.05.2024 / 17:40 CET/CEST Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Disclosure of Shareholdings Published, 08/05/2024   Notification ID: 95e58c52-be79-4dff-913a-3d312fe9da73 Notification of Collective Investment Schemes PART 1: LICENSEE Company name and head office of the licensee resp. for foreign collective investment schemes, which are not authorized for sale and are not dependent from a group of companies, company name and head office of the fund administration or the investment company: Company: UBS Fund Management (Switzerland) A City: Basel Country: Switzerland PART 2: COLLECTIVE INVESTMENT SCHEME/S Name of collective investment scheme/s which hold/s individually 3% or more voting rights PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION Date of the act that creates the obligation to notify: 30.04.2024 Date of transfer of equity securities (if different from date of the act which creates the obligation to notify): Facts and circumstances triggering the obligation to notify (art. 22 para. 1 b FMIO-FINMA): Acquisition Sale Creation of a group Change in group composition Termination of a group Discretionary exercise of voting rights Securities lending and comparable transactions Exercise, non-exercise or expiration of derivative holdings Granting (writing) of derivative holdings Capital increase Capital reduction Ipso jure transfer or transfer due to a decision by a court or public authority Change in the information subject to the obligation to notify Other X Disclosure triggered due to the absorption merger (“Absorptionsfusion”) between Credit Suisse Funds AG and UBS Fund Management (Switzerland) AG and the aggregation of the relevant interest of both entities as upon merger Credit Suisse Funds AG ceased to exist and UBS Fund Management (Switzerland) AG was the surviving entity. Total of voting rights below 3% If the participation falls below the threshold of 3% (purchase positions and sale positions), no indication in Part 4 or Part 5 is required. Total of voting rights <3%   PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA   Total of all purchase positions: Total of all equity securities or equity related securities (item 1), number of voting rights that can be exercised at one’s own discretion (item 3) and derivative holdings (item 4) Number of voting rights Percentage S1 = [1.1] + [3.1] + [4.1] S2 = [1.2] + [3.2] + [4.2] 2,413,177 4.356% Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:  55,400,000    Equity securities or equity related securities   Shares Number Voting rights1     Number Percentage2 Registered share 2,413,177 2,413,177 4.356%   Total   [1.1] 2,413,177 [1.2] 4.356% Whether exercisable or not Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA) Securities lending and comparable transactions in equity securities Of the equity securities mentioned in item 1 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):     Shares     Number     Proportion of voting rights   Nature of the legal transaction Agreed date of return transfer or, if there is a right to choose, whether this applies to the contracting party subject to the obligation to notify or to the counterparty Voting rights that can be exercised at one's own discretion The following voting rights were delegated by a third party and can be exercised at one's own discretion. Voting rights Is the person who has full discretionary powers to exercise voting rights directly or indirectly controlled? Yes  No   Derivative holdings Conversion and share purchase rights (such as call-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) share sale rights and other derivative holdings: Type of rights Number of rights Number of voting rights conferred Security ID number (ISIN) if available or basic terms     Number Percentage2 Identity of issuer, subscription ratio, exercise price, exercise period, exercise type [4.1] [4.2] Total 2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA) Securities lending and comparable transactions in derivative holdings Of the derivative holdings mentioned in item 4 above, the following part is held due to securities lending and comparable transactions (art. 17 FMIO-FINMA):     Nature of the legal transaction     Number of rights   Number of reported voting rights     Proportion of voting rights Agreed date of return transfer or, if there is a right to choose, whether this applies to the contracting party subject to the obligation to notify or to the counterparty PART 5: SALE POSITIONS PURSUANT TO ART. 14 PARA. 1 B FMIO-FINMA Total of all sale positions:  Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting rights pursuant to the entry in the commercial register (see Central Business Names Index) or Publication according to art. 115 para. 3 FMIO:  55,400,000  Derivative holdings Share sale rights (such as put-options according to art. 15 para. 2 a FMIO-FINMA), granted (written) conversion and share purchase rights and other derivative holdings: Type of rights Number of rights Number of voting rights conferred Security ID number (ISIN) if available or basic terms     Number Percentage2 Identity of issuer, subscription ratio, exercise price, exercise period, exercise type Total 2 Calculated on the basis of the total number of voting rights pursuant to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA) 10.05.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Language:	English
Company:	BB BIOTECH AG
	Schwertstrasse 6
	8200 Schaffhausen
	Switzerland
Internet:	www.bbbiotech.ch

End of News	EQS News Service

1900663  10.05.2024 CET/CEST